ECO Animal Health Group plc (LSE:EAH) has continued to build out its vaccine pipeline in recent weeks, announcing on 17 September 2026 that the US Department of Agriculture's Center for Veterinary Biologics had approved field safety data for its ECOVAXXIN MS poultry vaccine. The milestone follows the product's European launch in July and an August licensing deal for a sheep vaccine candidate, as the group seeks to move beyond its long reliance on a single core product.
What the company does
ECO Animal Health develops and sells animal health products, primarily for the poultry and pig sectors, through a global network spanning China, North America, Latin America, South East Asia and other markets. Its established business has been built around antibiotic and pharmaceutical products for livestock, and the group invests heavily in R&D, spending £8.8m in the year to March 2026.
Latest developments
ECOVAXXIN MS, a vaccine targeting Mycoplasma synoviae infection in poultry, is the first commercial product from the group's development pipeline. It received EU marketing authorisation in December 2025 and was launched after the financial year end, with first orders received. The company has said it expects US approval by the end of 2026, and dossiers have also been submitted in Thailand and Argentina.
On 12 August the company announced an exclusive in-licensing agreement with Vaxinano for a late-stage sheep vaccine candidate against toxoplasmosis, a parasitic disease that can cause abortion and stillbirth in sheep. Management estimated peak annual sales of around £10m in the UK and Europe alone, with terms including a modest upfront fee, a development milestone and royalties. Separately, Didier Branellec was appointed as a non-executive director in September.
Financial and dividend picture
Results for the year ended 31 March 2026, published on 15 July, showed revenue up 10% to £87.5m, or 14% at constant currency. Gross margin improved to 48.6% from 45.1%, adjusted EBITDA rose 16% to £8.5m, and profit before tax increased 35% to £5.4m. Earnings per share were 3.26p. Net cash at the year end was £25.4m, about 61% of which was held in China. No dividend was proposed, with the company choosing to reinvest in its pipeline, though it has indicated it may consider a progressive dividend policy in future. The group also renewed its revolving credit facility in June.
Sector and index context
ECO Animal Health (LSE:EAH) is one of the healthcare-related constituents of the FTSE AIM All Share Index. The global animal health market is shaped by livestock production trends, disease outbreaks, regulation and the push to reduce antibiotic use in farming, which supports demand for vaccines. The group competes with much larger multinational animal health businesses, making pipeline execution and regulatory approvals especially important.
Key risks
Demand in China, a major market, weakened in the final quarter of the last financial year, and a large share of cash is held there. Results have historically been weighted towards the second half. The company carries a £3.6m receivables provision, and early commercial uptake of the new vaccine is still unproven. Regulatory timelines for further approvals may slip.
What to watch next
Management expects profitability for the current year to be in line with market expectations, again weighted to the second half. Investors will watch for US approval of ECOVAXXIN MS, sales traction in Europe, progress on the ECOVAXXIN MG poultry vaccine and a bivalent pig vaccine, and interim results covering the six months to September.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...